Xia Han

1.6k total citations
8 papers, 312 citations indexed

About

Xia Han is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Xia Han has authored 8 papers receiving a total of 312 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 3 papers in Molecular Biology and 3 papers in Cancer Research. Recurrent topics in Xia Han's work include CAR-T cell therapy research (4 papers), Cancer Genomics and Diagnostics (3 papers) and Acute Lymphoblastic Leukemia research (2 papers). Xia Han is often cited by papers focused on CAR-T cell therapy research (4 papers), Cancer Genomics and Diagnostics (3 papers) and Acute Lymphoblastic Leukemia research (2 papers). Xia Han collaborates with scholars based in United States, Germany and Austria. Xia Han's co-authors include Bruce L. Levine, Abhijit Chakraborty, David L. Porter, Edward Waldron, Rakesh Awasthi, Patricia A. Wood, Noelle V. Frey, Simon F. Lacey, Karen Thudium Mueller and Stephan A. Grupp and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Xia Han

8 papers receiving 301 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Xia Han United States	4	269	121	69	64	64	8	312
Monalisa Ghosh United States	9	170 0.6×	87 0.7×	26 0.4×	63 1.0×	56 0.9×	45	308
Kyogo Suzuki Japan	6	185 0.7×	167 1.4×	44 0.6×	80 1.3×	55 0.9×	15	333
Erin Mullane United States	7	270 1.0×	49 0.4×	70 1.0×	57 0.9×	65 1.0×	15	298
Martina Schüßler‐Lenz Germany	6	349 1.3×	180 1.5×	119 1.7×	127 2.0×	103 1.6×	9	445
Vania Aikawa United States	4	291 1.1×	136 1.1×	128 1.9×	105 1.6×	68 1.1×	4	356
Silke Jamitzky Germany	7	296 1.1×	119 1.0×	50 0.7×	198 3.1×	68 1.1×	9	390
Sabarinath Venniyil Radhakrishnan United States	12	219 0.8×	119 1.0×	38 0.6×	112 1.8×	38 0.6×	28	332
Daosheng Huang China	8	289 1.1×	187 1.5×	95 1.4×	146 2.3×	115 1.8×	12	464
Carla A. Jaeger-Ruckstuhl United States	7	244 0.9×	99 0.8×	47 0.7×	154 2.4×	77 1.2×	12	341
Yonggui Tian China	7	280 1.0×	126 1.0×	64 0.9×	167 2.6×	70 1.1×	8	377

Countries citing papers authored by Xia Han

Since Specialization

Citations

This map shows the geographic impact of Xia Han's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xia Han with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xia Han more than expected).

Fields of papers citing papers by Xia Han

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xia Han. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xia Han. The network helps show where Xia Han may publish in the future.

Co-authorship network of co-authors of Xia Han

This figure shows the co-authorship network connecting the top 25 collaborators of Xia Han. A scholar is included among the top collaborators of Xia Han based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xia Han. Xia Han is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Zeidan, Amer M., Pierre Fenaux, Xia Han, et al.. (2023). Molecular Measurable Residual Disease (MRD) Clearance (≤1%) Is Associated with Improved Clinical Outcomes in Patients with Higher-Risk Myelodysplastic Neoplasms (HR-MDS): An Exploratory Analysis of Stimulus-MDS1 in Patients Receiving Sabatolimab or Placebo + Hypomethylating Agent (HMA). Blood. 142(Supplement 1). 3236–3236. 3 indexed citations

Mo, Tingting, et al.. (2022). A Retrospective Study of Rare Listeria Meningoencephalitis in Immunocompetent Children in China. Frontiers in Neurology. 13. 827145–827145. 1 indexed citations

Jäger, Ulrich, Nina Worel, Joseph P. McGuirk, et al.. (2021). Safety and efficacy of tisagenlecleucel (tisa-cel) plus pembrolizumab (pembro) in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): Updated analysis of the phase 1b PORTIA study.. Journal of Clinical Oncology. 39(15_suppl). e19537–e19537. 5 indexed citations

Jaeger, Ulrich, Michael Bishop, Gilles Salles, et al.. (2020). Myc Expression and Tumor-Infiltrating T Cells Are Associated with Response in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Treated with Tisagenlecleucel in the Juliet Trial. Blood. 136(Supplement 1). 48–49. 16 indexed citations

Voss, Martin H., David Chen, Albert Reising, et al.. (2018). PTEN Expression, Not Mutation Status in TSC1, TSC2, or mTOR, Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial. Clinical Cancer Research. 25(2). 506–514. 29 indexed citations

Mueller, Karen Thudium, Shannon L. Maude, David L. Porter, et al.. (2017). Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. Blood. 130(21). 2317–2325. 253 indexed citations

Voss, Martin H., David Chen, Mahtab Marker, et al.. (2017). Tumor genomic analysis for 128 renal cell carcinoma (RCC) patients receiving first-line everolimus: Correlation between outcome and mutations status in MTOR, TSC1, and TSC2.. Journal of Clinical Oncology. 35(6_suppl). 484–484. 3 indexed citations

Mueller, Karen Thudium, Abhijit Chakraborty, Patricia A. Wood, et al.. (2016). Cellular Kinetics of Chimeric Antigen Receptor T Cells (CTL019) in Patients with Relapsed/Refractory CD19+ Leukemia. Blood. 128(22). 220–220. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact